The BioIndustry Association (BIA) believes that the funding for regenerative medicine announced as part of a package of measures by the Office for Life Sciences (OLS) in its “Life Sciences Blueprint” will help the UK capitalise fully on its leading global position in regenerative medicine.
The OLS has announced £18 million funding from the Technology Strategy Board for a Regenerative Medicine programme of investment to support key areas of commercial R&D and the development of R&D partnerships, supported by additional funding of £3.5 million from the Medical Research Council, the Engineering and Physical Sciences Research Council and the Biotechnology and Biological Sciences Research Council
Richard Archer, Chair of the BIA RegenMed Industry Group, said:
“The funding announced t by the Office for Life Sciences will provide a significant boost for this rapidly developing part of the UK life sciences sector. In combination with the other measures announced by the OLS, this funding will provide a solid foundation on which the UK’s regenerative medicine industry can grow.”